WO2008146308A2 - Process for the preparation of ivabradine hydrochloride and polymorph thereof - Google Patents

Process for the preparation of ivabradine hydrochloride and polymorph thereof Download PDF

Info

Publication number
WO2008146308A2
WO2008146308A2 PCT/IN2008/000341 IN2008000341W WO2008146308A2 WO 2008146308 A2 WO2008146308 A2 WO 2008146308A2 IN 2008000341 W IN2008000341 W IN 2008000341W WO 2008146308 A2 WO2008146308 A2 WO 2008146308A2
Authority
WO
WIPO (PCT)
Prior art keywords
ivabradine
acid
process according
solvent
formula
Prior art date
Application number
PCT/IN2008/000341
Other languages
French (fr)
Other versions
WO2008146308A3 (en
WO2008146308A9 (en
Inventor
Satyendra Pal Singh
Gajendra Singh
Lalit Wadhwa
Original Assignee
Ind-Swift Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40075646&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2008146308(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ind-Swift Laboratories Limited filed Critical Ind-Swift Laboratories Limited
Priority to JP2010509952A priority Critical patent/JP5632279B2/en
Priority to RU2009149375/04A priority patent/RU2473544C2/en
Priority to US12/602,348 priority patent/US8212026B2/en
Priority to KR1020097026828A priority patent/KR101478855B1/en
Priority to EP08763748A priority patent/EP2162438A4/en
Publication of WO2008146308A2 publication Critical patent/WO2008146308A2/en
Publication of WO2008146308A9 publication Critical patent/WO2008146308A9/en
Publication of WO2008146308A3 publication Critical patent/WO2008146308A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the present invention relates to a novel process for the preparation of ivabradine hydrochloride, an useful antianginal agent. Further the present invention relates to novel amorphous form of ivabradine hydrochloride and process for the preparation thereof.
  • Ivabradine hydrochloride of formula I has very valuable pharmacological and therapeutic properties, and is useful in many cardiovascular diseases such as angina pectoris, myocardial infarct and associated rhythm disturbances and is chemically known as (S)-7,8-dimethoxy-3- ⁇ 3- ⁇ 7V-[(4,5-dimethoxybenzocyclobut-l-yl)methyl]-iV-(methyl)amino)propyl)-l,3,4,5-tetrahydro-2H- 3-benzazepin-2-one.
  • Ivabradine hydrochloride is first disclosed in U.S. Patent No. 5,296,482.
  • the disclosed process comprises the condensation of (S)-N-[(4,5-dimethoxybenzocyclobut-l-yl)-methyl]-7V- (methyl)amine of Formula II,
  • the methyl amine derivative of formula II is prepared by the reduction of l-cyano-4,5- dimethoxybenzocyclobutane of Formula V,
  • racemic compound of methyl amine derivative of formula II The racemic compound is resolved to (+) isomer of methyl amine derivative of formula II with (d)-camphosulphonic acid.
  • Benzazepine derivative of formula III is prepared by the reaction of sodium iodide with 7,8- dimethoxy-3-[3-chloropropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula VI,
  • aqueous hydrochloride in the preparation of ivabradine hydrochloride is also not suggested because the removal of hydrochloric acid by distillation may lead to the decomposition and results in the generation of impurities and hence further purification is required. Also, use of highly flammable and large quantities of organic solvent in the preparation of benzazepine intermediate of formula IV makes this process unattractive for large scale production.
  • amorphous forms in a number of drugs exhibit different dissolution characteristics and in some cases different bioavailability patterns compared to the crystalline form (Econno T., Chem. Phazm Bull., 1990; 38: 2003-2007). For some therapeutic indications, one bioavailability pattern may be favoured over another.
  • An amorphous form of cefuroxime axietil is an example of one amorphous drug exhibiting much higher bioavailability than the crystalline forms, which leads to the selection of the amorphous form as the final drug substance for cefuroxime axietil pharmaceutical dosage form development.
  • aqueous solubility of crystalline atorvastatin calcium is lower than its amorphous form, which may result in the difference in their in vivo bioavailability. Therefore, it is desirable to have amorphous forms of drugs with high purity to meet the needs of regulatory agencies and also highly reproducible processes for their preparation.
  • One aspect of the present invention is to provide a process for the preparation of highly pure ivabradine hydrochloride of formula I which comprises: a. condensing methylamine derivative of formula II Formula II
  • Another aspect of the present invention is to provide a novel form of ivabradine hydrochloride i.e. amorphous ivabradine hydrochloride.
  • One another aspect of the present invention provides a process for the preparation of amorphous ivabradine hydrochloride which comprises: a. hydrogenating the benzazepine intermediate of formula IV with palladium on carbon in glacial acetic acid under the atmosphere of hydrogen gas to get ivabradine;
  • ivabradine with a solution of organic acid in a suitable solvent to get ivabradine acid addition salt; c. optionally purifying the ivabradine acid addition salt; d. hydrolysing ivabradine acid addition salt with aqueous base in a suitable solvent; and e. treating the resulting ivabradine in situ with alcoholic hydrogen chloride in organic solvent.
  • a process for the preparation of highly pure ivabradine hydrochloride which comprises: treating ivabradine with alcoholic hydrogen chloride in suitable solvent to prepare its hydrochloride salt.
  • One more another aspect of the present invention is to provide a process for the preparation of amorphous ivabradine hydrochloride which comprises: treating ivabradine with a solution of organic acid in a suitable solvent to get ivabradine acid addition salt; optionally purifying the ivabradine acid addition salt; hydrolysing ivabradine acid addition salt with base in a suitable solvent; and treating the resulting ivabradine with alcoholic hydrogen chloride in organic solvent.
  • Yet another aspect of the present invention is to provide a process for preparing amorphous ivabradine hydrochloride comprising: a. treating ivabradine hydrochloride with base in a suitable solvent; and b. treating the resulting ivabradine with alcoholic hydrogen chloride in organic solvent.
  • Still yet another aspect of the present invention is to provide a process for the preparation of amorphous ivabradine hydrochloride which comprises: a. dissolving ivabradine hydrochloride in a mixture of lower alkanol and ketone at ambient temperature; b. heating the solution to 40-50°C; c. distilling the solvent; and d. isolating amorphous ivabradine hydrochloride.
  • a process for preparing ⁇ crystalline form of ivabradine hydrochloride comprising the steps of: a. heating a solution ivabradine hydrochloride in suitable solvent; b. distilling off some of the solvent; c.
  • Ivabradine acid addition salts prepared in the present invention also forms the inventive part of the invention.
  • Ivabradine oxalate is isolated as crystalline solid and is another inventive part of the invention.
  • Figure 1 is a powdered X-ray diffraction pattern for amorphous ivabradine hydrochloride.
  • Figure 2 is a powdered X-ray diffraction pattern for ⁇ crystalline form of ivabradine hydrochloride.
  • Figure 3 is a powdered X-ray diffraction pattern for ivabradine oxalate.
  • Figure 4 is a DSC thermogram for ivabradine oxalate.
  • the instant invention relates to an efficient and industrially advantageous process for the preparation of highly pure ivabradine or a pharmaceutically acceptable salt and in particular ivabradine hydrochloride.
  • One aspect of the present invention relates to an improved process for the preparation of highly pure ivabradine hydrochloride by initially condensing methylamine derivative of formula II with benzazepine derivative of formula III to form benzazepine intermediate of formula IV in the presence of a base, in a polar aprotic or protic solvents.
  • the base can be selected from alkali metal carbonates, bicarbonates and hydroxides and preferably potassium carbonate.
  • the polar aprotic or protic solvent is selected from tetrahydrofuran, acetone, acetonitrile, dimethylformamide, dimethylsulfoxide, water, isopropanol, Ci-C 4 linear aliphatic alcohols such as methanol, ethanol etc.
  • the solvent is dimethylformamide or dimethylsulfoxide and most preferably the solvent is dimethylformamide. It is advantageous to use dimethylformamide during condensation reaction because reaction rate is faster and it takes only 2-3 hours for completion of reaction as compared to prior art processes wherein 18 hours are required in acetone. Reaction is conducted at 30-75°C and preferably at 50- 60°C. The completion of reaction is monitored by high performance liquid chromatography. After completion of the reaction, the reaction mass is cooled to ambient temperature and diluted with water. The product is extracted in organic solvent from aqueous layer and some impurities remain in the aqueous layer.
  • the solvent can be selected from halogenated hydrocarbon such as methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform and aliphatic ester such as ethyl acetate and preferably methylene chloride is used. Thereafter, solvent is distilled off completely and the product is purified by acid base wash treatment. Specifically the residue is treated with hydrochloric acid in water and washed with solvent such as ethyl acetate, thereafter the aqueous layer is neutralized with base and the desired compound is extracted in organic solvent.
  • the organic solvent can be selected from halogenated hydrocarbons and aliphatic esters as mentioned above and preferably ethyl acetate is used.
  • the product is obtained in high purity and no chromatographic purification is required. It has also been found that during condensation process an unknown impurity has also been formed, which is not easily removed by using the prior art isolation process and hence decreases the purity of the condensed product. But during the process of present invention, it is observed that the said unknown impurity can be easily removed by extracting the desired product from the reaction mixture with halogenated solvents such as methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform. This further avoids the use of tedious chromatographic purification.
  • benzazepine intermediate of formula IV is most preferably prepared by condensing methylamine derivative of formula II with 7,8- dimethoxy-3-[3-iodopropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula III in demineralized water and in the presence of a base.
  • the condensation reaction is carried out at 45-60°C preferably at 5O-55°C and it takes 10-20 hours for completion of reaction.
  • the progress of reaction is monitored by high performance liquid chromatography (HPLC).
  • HPLC high performance liquid chromatography
  • the product is extracted in lower aliphatic ester solvent such as ethyl acetate.
  • Ethyl acetate layer is further treated with aqueous acidic solution and the resulting layers are separated.
  • the aqueous layer is treated with basic solution and the product is extracted in lower aliphatic ester solvent such as ethyl acetate.
  • Ethyl acetate layer is removed by known methods such as evaporation, distillation with or without vacuum etc to get benzazepine intermediate of formula IV.
  • the base is used in the condensation step can be selected from alkali metal carbonates, bicarbonates and hydroxides and preferably potassium carbonate.
  • the intermediates II and III can be prepared by the methods reported in the prior art with minor modifications. Specifically the methyl amine derivative of Formula II is prepared by the reduction of l-cyano-4,5-dimethoxybenzocyclobutane of formula V
  • hydrochloride salt is prepared by treating the amino derivative with alcoholic hydrogen chloride; ethereal hydrogen chloride such as ethanol hydrogen chloride, isopropyl acetate hydrogen chloride, isopropyl ether hydrogen chloride etc.
  • Hydrochloric acid salt of the obtained amino intermediate is further condensed with ethyl chloroformate in the presence of a suitable base to prepare the corresponding amide.
  • the resulting amide is reduced with lithium aluminium hydride in tetrahydrofuran to prepare racemic methyl amine intermediate of formula II.
  • Racemic intermediate is further resolved with suitable resolving agent such as (d)-camphosulphonic acid to produce desired (+) isomer methyl amine of formula II which can optionally be used in oily form or can be isolated.
  • the said process is very useful during its application at large-scale production because borane dimethyl sulphide complex is stable at room temperature hence its storage and handing is not difficult during large scale production.
  • the benzazepine compound of formula III is prepared by the reaction of 7,8- dimethoxy-3-[3-chloropropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula VI with sodium iodide in acetone followed by its purification by slurry washing of the residue with acetone.
  • the intermediates of formula V and VI are prepared by the methods reported in the literatures (T. Kametani et al, Tetrahedron 1973; vol. 29; pages 73-76 and Reiffer M. et al., J. Med. Chem.. 1990; vol 33 (5): 1496-1504).
  • the intermediate of formula V can also be prepared by the reaction of 6-bromovaretraldehyde with cyanoacetic acid in the presence of ammonium acetate and in solvents optionally selected from pyridine, toluene, benzene etc. or mixtures thereof.
  • the isolated intermediate is further reduced with sodium borohydride in the presence of aqueous base.
  • bases are selected from sodium bicarbonate, sodium carbonate, potassium hydroxide, sodium hydroxide or mixtures thereof to get ⁇ -(2-bromo-4,5-dimethoxyphenyl)- ⁇ -cyanopropionic acid.
  • the intermediate of formula VI can also be prepared by the halogenation of 3,4- dimethoxyphenyl acetic acid with some halogenating agents such as thionyl chloride in chlorinated solvents such as methylene dichloride.
  • the obtained chloro compound is further condensed with aminoacetaldehyde dimethyl acetal in the presence of a suitable base to prepare corresponding amide derivative.
  • the ring closure of resulting amide into benzazepin moiety is carried out in presence of an acid, for example, hydrochloric acid, glacial acetic acid or mixtures thereof.
  • Obtained benzazepin moiety is further alkylated with l-bromo-3-chloro-propane in presence of a suitable base such as potassium tertiary butoxide in an organic solvent to obtain 7,8-dimethoxy-3-[3-chloropropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula VI.
  • the organic solvents can be selected from acetone, dimethylsulfoxide, dimethylformamide, etc. or mixtures thereof.
  • Benzazepine intermediate of formula IV prepared by the processes of present invention is hydrogenated and converted into highly pure ivabradine or a pharmaceutically acceptable salt thereof.
  • the condensed product i.e. (S)-7,8-dimethoxy-3- ⁇ 3 ⁇ N-[(4,5-dimethoxybenzocyclobut- l-yl)methyl]-N-(methyl)amino)propyl)-l,3-dihydro-2H-3-benzazepin-2-one of formula IV is converted to ivabradine hydrochloride.
  • the compound of formula IV is catalytically hydrogenated using palladium on carbon catalyst in acetic acid under hydrogen pressure of 1-7 kg/cm .
  • the hydrogenation reaction is conducted at ambient temperature and it takes 4-10 hours for completion of reaction, which is monitored by high performance liquid chromatography (HPLC).
  • the catalyst is filtered out and the product is extracted in organic solvent from filtrate or acetic acid is removed by distillation from the filtrate.
  • the organic solvent consists of methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform.
  • the filtrate is further treated with dilute hydrochloric acid and extracted with same organic solvent.
  • the aqueous layer is washed with organic solvent such as ethyl acetate to remove impurities and neutralized with base like aqueous sodium hydroxide.
  • organic solvent such as ethyl acetate
  • the desired compound is extracted in organic solvent.
  • the organic solvent can be selected from above mentioned solvents such as halogenated hydrocarbon and aliphatic esters and preferably ethyl acetate is used.
  • the ivabradine is isolated; otherwise organic layer itself is treated with alcoholic hydrogen chloride to prepare highly pure ivabradine hydrochloride. It is advantageous to dry the organic layer using drying agent such as sodium sulfate or the like before adding alcoholic hydrogen chloride.
  • ivabradine of formula I is converted into pharmaceutically acceptable acid addition salts using alcoholic acid mixture.
  • the hydrochloride salt preparation is carried out using alcoholic hydrogen chloride.
  • a solution of alcoholic hydrogen chloride is prepared by purging dry hydrogen chloride in alcohol by following the methods reported in prior art.
  • the percentage of hydrogen chloride in alcohol is preferably selected between 10-25%.
  • the alcohol used in the solution of alcohol-hydrogen chloride is selected from C 1 -C 4 branched or linear aliphatic alcohols and more preferably the solvent is methanol, ethanol, n-butanol or isopropanol and most preferably the solvent is methanol and isopropanol.
  • the precipitated ivabradine hydrochloride is isolated in high yield and purity of greater than 99.0% area by HPLC.
  • XRD pattern shows that material is amorphous in nature, substantially as depicted in Figure 1.
  • Amorphous Ivabradine hydrochloride is novel and forms one aspect of the present invention.
  • Amorphous ivabradine hydrochloride is further characterized by a differential scanning calorimetry ("DSC") thermogram, which shows one endothermic peak around 194 °C due to melting.
  • DSC differential scanning calorimetry
  • Another aspect of the present invention relates to the preparation of highly pure amorphous ivabradine hydrochloride from ivabradine through ivabradine acid addition salts.
  • the ivabradine is treated with a solution of organic acid in solvent selected from lower aliphatic ketone such as acetone; ester such as ethyl acetate and nitrile such as acetonitrile to prepare ivabradine acid addition salt.
  • the organic acid can be selected from acetic acid, propionic acid, maleic acid, fumaric acid, tartaric acid, oxalic acid, citric acid, benzoic acid, methanesulphonic acid, isethionic acid, benzenesulphonic acid, toluenesulphonic acid and the like.
  • the acid is selected from oxalic acid, citric acid, methanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid and most preferably the acid is oxalic acid.
  • the ivabradine oxalate is prepared by treating ivabradine with oxalic acid in acetone and reaction mass is stirred at ambient temperature for sufficient tine to prepare the oxalate salt.
  • the oxalate salt is isolated by filtration and optionally recrystallized in acetonitrile to isolate pure ivabradine oxalate.
  • the ivabradine oxalate is isolated as crystalline solid and may be characterized by at least one of Karl Fisher or TGA, X-Ray power diffraction (XRD), or differential scan calorimetry (DSC).
  • Crystalline ivabradine oxalate is characterized by powdered X-ray diffraction patterns having peaks at about 2.04, 2.13, 4.26, 7.06, 8.02, 8.53, 9.32, 10.91, 13.63, 15.07, 16.11, 16.44, 17.48, 18.37, 19.32, 20.38, 20.94, 21.95, 23.61, 24.26, 27.54 and 33.07 degrees two theta, substantially as depicted in Figure 3.
  • Crystalline ivabradine oxalate is further characterized by a differential scanning calorimetry ("DSC”) thermogram, which shows one endothermic peak around 110°C due to melting, substantially as depicted in Figure 4.
  • DSC differential scanning calorimetry
  • X-ray diffraction of amorphous ivabradine hydrochloride and crystalline ivabradine oxalate are measured on a PANalytical X' Pert Pro diffractometer with Cu radiation and expressed in terms of two-theta, d-spacings and relative intensities.
  • DSC analysis was performed using a Mettler Toledo 822 Star 6 .
  • the crucible was crimped and punched prior to analysis.
  • the weight of the samples was about 4-6 mg; the samples were scanned at a rate of 5 °C/min from 30 °C to 250 °C.
  • the oven was constantly purged with nitrogen gas at a flow rate of 80 ml/min. Standard 40 ⁇ l aluminum crucibles covered by lids with one hole were used.
  • the isolated acid addition salt of ivabradine is recrystallized in a suitable organic solvent such as acetonitrile
  • Acid addition salt of ivabradine is hydrolyzed with a suitable base in demineralized water to get ivabradine.
  • the base can be selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate and preferably sodium hydroxide is used.
  • the desired compound is extracted in organic solvent.
  • the organic solvent can be selected from halogenated hydrocarbon and aliphatic esters and preferably ethyl acetate is used. Ethyl acetate is distilled out to isolate the ivabradine as oil. Crude ivabradine is further dissolved in a suitable organic solvent such as acetone, ethyl acetate preferably in acetone.
  • the pH of the resulting clear solution is adjusted to 1.0 to 2.0 with alcoholic hydrogen chloride and stirred for 30 to 60 minutes to get highly pure amorphous ivabradine hydrochloride. It is advantageous to dry the organic layer using drying agent such as sodium sulfate or the like before adding alcoholic hydrogen chloride.
  • Amorphous ivabradine hydrochloride is isolated by removing the solvent from the reaction mixture by known methods such as evaporation, distillation with or without vacuum etc.
  • the amorphous ivabradine hydrochloride is further stirred for 30 to 60 minutes in a suitable organic solvent such as n-heptane, n-hexane and cyclohexane then filtered and washed with same organic solvent to get highly pure amorphous ivabradine hydrochloride.
  • a suitable organic solvent such as n-heptane, n-hexane and cyclohexane then filtered and washed with same organic solvent to get highly pure amorphous ivabradine hydrochloride.
  • amorphous ivabradine hydrochloride in yet another aspect of the present invention is provided a process for the preparation of amorphous ivabradine hydrochloride by dissolving ivabradine hydrochloride in a mixture of lower alkanol and ketone at ambient temperature and further heated to 40-50°C, distilling out the solvent under vacuum, isolating amorphous ivabradine hydrochloride.
  • the lower alkanol can be selected from methanol, ethanol, propanol, isopropanol and preferably methanol is used.
  • the ketone can be selected from acetone, methyl ethyl ketone, methyl isobutyl ketone and preferably acetone is used. Mixture of lower alkanol and ketone is used in a ratio of 1: 2-6 (v/v) more preferably 1 :3 (v/v) and most preferably 1:2 (v/v).
  • ivabradine hydrochloride is dissolved in a mixture of methanol and acetone by simple stirring at room temperature without using prior heating.
  • Amorphous ivabradine hydrochloride is isolated by removing the solvent from the reaction mixture by known methods such as evaporation, distillation with or without vacuum etc. Alternatively the isolation of highly pure amorphous ivabradine hydrochloride is carried out by stirring the amorphous ivabradine hydrochloride in a suitable organic solvent such as n-heptane, n-hexane and cyclohexane for about 30 to 60 minutes followed by filtering and washingd with same organic solvent to get highly pure amorphous ivabradine hydrochloride. In yet another aspect of the present invention amorphous ivabradine hydrochloride can also be prepared from ⁇ crystalline form of ivabradine hydrochloride.
  • the crystalline ivabradine hydrochloride is treated with suitable base and in a suitable solvent followed by regeneration of ivabradine hydrochloride from the solution of isopropyl alcohol/hydrogen chloride to get amorphous ivabradine hydrochloride.
  • the base can be selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate.
  • the solvent can be selected from ethyl acetate, isopropyl acetate, methyl isobutyl ketone and acetone.
  • the ⁇ crystalline form of ivabradine hydrochloride can also be prepared by recrystallization of ivabradine hydrochloride in suitable organic solvent such as acetonitrile, followed by addition of lower aliphatic ketone, ester, straight branched or cyclic ethers or mixtures thereof heat the mixture, removed solvents and recovered the ⁇ crystalline form of ivabradine hydrochloride.
  • suitable organic solvent such as acetonitrile
  • the ⁇ crystalline form of ivabradine hydrochloride can also be prepared from amorphous ivabradine in suitable organic solvent such as lower aliphatic ketone, ester, straight branched or cyclic ethers or nitriles or mixtures thereof.
  • suitable organic solvent such as lower aliphatic ketone, ester, straight branched or cyclic ethers or nitriles or mixtures thereof.
  • the lower aliphatic ketonic solvents can be selected from methyl isobutyl ketone, acetone or the like.
  • the esters can be selected from ethyl acetate and isopropyl acetate.
  • the ether can be selected from isopropyl ether, tetrahydrofuran and the like.
  • the nitrile can be acetonitrile and the like.
  • Ivabradine hydrochloride is taken in suitable solvent and heated at 60-90°C for sufficient time to transform to ⁇ crystalline
  • Example 1 Preparation of Ivabradine hydrochloride Stepl: Preparation of (S)-7,8-dimethoxy-3- ⁇ 3- ⁇ N-f(4,5-dimethoxybenzocvclobut-l-yl) methyll-N-(methvDamino)propyl)- l,3-dihydro-2H-3-benzazepin-2-one
  • the reaction mixture was extracted with methylene dichloride (400ml x 200ml) and the layers were separated. Methylene chloride was distilled off completely. To the residue, dimineralized water (200ml) and hydrochloric acid (50ml) were added and the aqueous solution is washed with ethyl acetate (200ml x 3). The layers were separated and to the aqueous layer 50 % (w/v) sodium hydroxide solution (120ml) was added at 25-30 °C.
  • the aqueous layer was extracted with ethyl acetate (400ml + 200 ml) and the combined ethyl acetate layer was washed with 5 %( w/v) sodium hydroxide solution (300ml). Ethyl acetate layer was dried over anhydrous sodium sulfate and then ethyl acetate was distilled out completely under vacuum to get the title compound.
  • Benzazepine compound (85g) obtained in step 1 was taken in acetic acid (700ml), and was hydrogenated under a hydrogen pressure (1-2 kg) at room temperature in the presence of Pd/C (10%, 7Og). Further hydrogenation was continued with 6-7 kg/cm 2 hydrogen gas pressure at 20 °C for 6-8 hours. After completion of hydrogenation (monitored by HPLC), the catalyst was filtered off and catalyst was washed with water (800ml). The filtrate was then extracted with methylene chloride (700ml) and to the aqueous layer hydrochloric acid solution (50ml) was added. The aqueous layer was again extracted with methylene dichloride (300ml x 3).
  • the combined organic layer was distilled off and to the residue dimineralized water (400ml) and hydrochloric acid solution (90 ml) were charged followed by ethyl acetate (400ml).
  • the reaction mixture was stirred at 30-35 °C for half an hour and the layers were separated.
  • the aqueous layer was again washed with ethyl acetate (500ml).
  • aqueous layer was treated with 50 % (w/v) sodium hydroxide solution (150ml).
  • the aqueous layer was extracted with ethyl acetate (400ml + 250ml) and combined ethyl acetate layer was washed with 5% (w/v) sodium hydroxide solution (400ml).
  • Combined ethyl acetate layers was acidified with aqueous hydrochloric acid and stirred. The layers were separated and pH of the aqueous layer was adjusted to 10.5-12.5 with aqueous sodium hydroxide solution. The aqueous layer is extracted with ethyl acetate (140ml + 60ml). Ethyl acetate was distilled out completely under vacuum to get the title compound.
  • Example 3 Preparation of amorphous ivabradine hydrochloride Benzazepine intermediate of formula IV (85g) was taken in acetic acid (700ml), and was hydrogenated under a hydrogen pressure (1-2 kg) at room temperature in the presence of Pd/C (10%, 7Og). Further hydrogenation was continued with 6-7 kg/cm 2 hydrogen gas pressure at 20 °C for 6-8 hours. After completion of hydrogenation (monitored by HPLC), the catalyst was filtered off and acetic acid was removed by distillation. To the residue demineralized water (360ml) and hydrochloric acid (40ml) were added followed by addition of ethyl acetate (200ml). The resulting mixture was stirred and the layers were separated.
  • the aqueous layer was washed with ethyl acetate (100ml). The pH of the aqueous layer was adjusted to 10.5-12.5 with aqueous sodium hydroxide solution and product was extracted in ethyl acetate (400ml). Ethyl acetate layer was dried over anhydrous sodium sulfate and then solvent was distilled out completely. The residue was taken in ethyl acetate (1020ml) and to this oxalic acid (34g) in acetone (68ml) was added slowly and was stirred for 3-4 hours at ambient temperature. The ivabradine oxalate obtained was filtered and recrystallized in acetonitrile.
  • Ivabradine oxalate was taken in demineralized water (340ml) and pH of the reaction mixture was adjusted to 10-12 with aqueous sodium hydroxide solution and stirred. The resulting mixture is then extracted with ethyl acetate (340ml). Ethyl acetate was distilled out completely. Thereafter, the residue was taken in acetone (220ml) and to this methanol-hydrogen chloride (30-35ml) was added slowly and was stirred for 30 minutes. The solvent was removed by distillation under reduced pressure.
  • Example 4 Preparation of amorphous ivabradine hydrochloride
  • Step-1 Preparation of ivabradine oxalate Ivabradine (44g) was dissolved in ethyl acetate (700ml) and to this oxalic acid (22g) in acetone (50ml) was added slowly and stirred for 3-4 hours at ambient temperature. The ivabradine oxalate, thus obtained was filtered, washed with ethyl acetate (100ml) and recrystallized in acetonitrile (350ml). XRD pattern shows that isolated ivabradine oxalate was crystalline in nature and depicted in Figure 2.
  • Step-2 Preparation of amorphous ivabradine hydrochloride
  • Ivabradine oxalate was taken in demineralized water (200ml) and to this aqueous sodium hydroxide solution (100ml) was added and stirred. The resulting mixture was extracted with ethyl acetate (250ml). Ethyl acetate layer was dried over anhydrous sodium sulfate and then solvent was distilled out completely. The resulting residue was taken in acetone (100ml) and to this methanol-hydrogen chloride (7ml) was added slowly and was stirred for 30 minutes. Thereafter the solvent was removed by distillation under reduced pressure.
  • n-heptane 100ml was added and stirred for 30 minutes, filtered, washed with n- heptane (50ml) and dried at 40-45 °C to obtain the title compound.
  • Example 5 Preparation of amorphous ivabradine hydrochloride Ivabradine hydrochloride (2Og) was dissolved in stirred mixture of acetone (100ml) and methanol (50ml) at ambient temperature. The solution was heated to 50 °C and the solvent was distilled off under reduced pressure. The amorphous product, thus obtained, was stirred with n- heptane (100ml). The reaction mixture was filtered, washed with n-heptane and dried at 40-45 °C under vacuum to obtain the title compound.
  • Example 6 Preparation of amorphous ivabradine hydrochloride ⁇ - Crystalline form of ivabradine hydrochloride (6 gm) was taken in water (30 ml) and basified by sodium hydroxide solution (50 %). Ivabradine, thus formed, was extracted with ethyl acetate (50 ml) and was dried over anhydrous sodium sulfate. Solvent was distilled off. Residue was taken in ethyl acetate (30ml) and isopropyl alcohol hydrogen chloride (5ml) was added slowly and was stirred for 2 hours. Product thus obtained was filtered, washed with ethyl acetate (6 ml) and dried at 55-60 0 C to obtained amorphous ivabradine hydrochloride having purity 99.93 % area by HPLC.
  • Ivabradine hydrochloride (47g) was taken in acetonitrile (940ml) and heated to 80 ⁇ 2 °C for 30 minutes till clear solution. Thereafter, half of the acetonitrile was distilled off and the reaction mass was cooled, filtered and washed with acetonitrile to get wet cake of the product. Obtained wet cake was further dissolved in ethyl acetate (611ml) at room temperature then heated the mixture to 75-80 0 C and maintained for 60 minutes. The reaction mixture was concentrated by distillation of about one third of ethyl acetate. The reaction mass was cooled, filtered, washed with ethyl acetate and dried under vacuum to obtain the title compound.
  • Example 8 Preparation of ⁇ crystalline form of ivabradine hydrochloride from amorphous form
  • ivabradine hydrochloride 4 gm was taken in ethyl acetate (60 ml) and heated to reflux for 30 minutes. Thereafter one third of ethyl acetate was distilled off and the reaction mass was cooled to 25-30 °C. The product obtained was filtered and dried to obtain the title compound having purity 99.89 % area by HPLC.
  • Example 9 Preparation of ⁇ crystalline form of ivabradine hydrochloride

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Catalysts (AREA)

Abstract

The present invention encompasses a process for the preparation of highly pure ivabradine hydrochloride by treating ivabradine with alcoholic hydrogen chloride. The invention further encompasses amorphous ivabradine hydrochloride and process for its preparation using suitable acid addition salts of ivabradine.

Description

PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE
AND POLYMORPH THEREOF
FIELD OF THE INVENTION
The present invention relates to a novel process for the preparation of ivabradine hydrochloride, an useful antianginal agent. Further the present invention relates to novel amorphous form of ivabradine hydrochloride and process for the preparation thereof.
BACKGROUND OF THE INVENTION
Ivabradine hydrochloride of formula I, has very valuable pharmacological and therapeutic properties, and is useful in many cardiovascular diseases such as angina pectoris, myocardial infarct and associated rhythm disturbances and is chemically known as (S)-7,8-dimethoxy-3-{3- {7V-[(4,5-dimethoxybenzocyclobut-l-yl)methyl]-iV-(methyl)amino)propyl)-l,3,4,5-tetrahydro-2H- 3-benzazepin-2-one.
Figure imgf000002_0001
Formula I
Ivabradine hydrochloride is first disclosed in U.S. Patent No. 5,296,482. The disclosed process comprises the condensation of (S)-N-[(4,5-dimethoxybenzocyclobut-l-yl)-methyl]-7V- (methyl)amine of Formula II,
Figure imgf000002_0002
Formula II
with 7,8-dimethoxy-3-[3-iodopropyl]-l ,3-dihydro-2H-3-benzazepin-2-one Formula III,
Figure imgf000002_0003
Formula III
in acetone and in presence of a base such as potassium carbonate. The resulting benzazepine intermediate of formula IV is purified by column chromatography, and
Figure imgf000003_0001
Formula IV
is further reduced with palladium hydroxide in glacial acetic acid, under the atmosphere of hydrogen gas to get ivabradine which is converted into its hydrochloride salt by the action of aqueous hydrochloric acid.
The methyl amine derivative of formula II is prepared by the reduction of l-cyano-4,5- dimethoxybenzocyclobutane of Formula V,
Figure imgf000003_0002
Formula V
with borane tetrahydrofuran complex which upon condensation with ethyl chloroformate and further reducion with lithium aluminium hydride in tetrahydrofuran resulted in racemic compound of methyl amine derivative of formula II. The racemic compound is resolved to (+) isomer of methyl amine derivative of formula II with (d)-camphosulphonic acid.
Benzazepine derivative of formula III is prepared by the reaction of sodium iodide with 7,8- dimethoxy-3-[3-chloropropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula VI,
Figure imgf000003_0003
Formula VI
in acetone and the resulting iodo intermediate is purified by dissolving it in water and extraction with dichloromethane.
It has been observed that the said process suffers from many drawbacks such as the use of borane-tetrahydrofuran complex which is unstable at room temperature and purification of intermediates and ivabradine by chromatographic techniques. The chromatographic technique for purification is cumbersome, tedious and difficult to utilize on an industrial scale.
The use of aqueous hydrochloride in the preparation of ivabradine hydrochloride is also not suggested because the removal of hydrochloric acid by distillation may lead to the decomposition and results in the generation of impurities and hence further purification is required. Also, use of highly flammable and large quantities of organic solvent in the preparation of benzazepine intermediate of formula IV makes this process unattractive for large scale production.
The above mentioned drawbacks call for an alternative and improved process for the preparation of highly pure ivabradine hydrochloride that would be commercially viable, reproducible on industrial scale and meets the needs of regulatory agencies.
Subsequent U.S. Patent 7,176,197 reports α crystalline form of ivabradine hydrochloride. Several other crystalline forms such as beta, gamma, delta, beta-d, gamma-d and delta-d are also reported by Les Laboratories. There is no data available in the prior art for the existence of amorphous ivabradine hydrochloride. Crystalline solids normally require a significant amount of energy for dissolution due to their highly organized, lattice like structures. For example, the energy required for a drug molecule to escape from a crystal is more than from an amorphous or a non-crystalline form. It is known that the amorphous forms in a number of drugs exhibit different dissolution characteristics and in some cases different bioavailability patterns compared to the crystalline form (Econno T., Chem. Phazm Bull., 1990; 38: 2003-2007). For some therapeutic indications, one bioavailability pattern may be favoured over another. An amorphous form of cefuroxime axietil is an example of one amorphous drug exhibiting much higher bioavailability than the crystalline forms, which leads to the selection of the amorphous form as the final drug substance for cefuroxime axietil pharmaceutical dosage form development. Additionally, the aqueous solubility of crystalline atorvastatin calcium is lower than its amorphous form, which may result in the difference in their in vivo bioavailability. Therefore, it is desirable to have amorphous forms of drugs with high purity to meet the needs of regulatory agencies and also highly reproducible processes for their preparation.
In view of the above, it is, therefore, desirable to provide an efficient, more economical, less hazardous and eco-friendly process for the preparation of highly pure ivabradine or a pharmaceutically acceptable salt thereof where impurity formation is less and hence avoids chromatographic purification and is convenient to operate on a commercial scale. Further, an amorphous form of ivabradine hydrochloride has also been provided in the present application for which the protection is sought. SUMMARY OF THE INVENTION
One aspect of the present invention is to provide a process for the preparation of highly pure ivabradine hydrochloride of formula I which comprises: a. condensing methylamine derivative of formula II
Figure imgf000005_0001
Formula II
with 7,8-dimethoxy-3-[3-iodopropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula III
Figure imgf000005_0002
Formula III
in a suitable polar solvent in the presence of a base to prepare benzazepine intermediate of formula IV;
Figure imgf000005_0003
Formula IV
b. reducing the compound of formula IV with palladium on carbon in glacial acetic acid under the atmosphere of hydrogen gas to get ivabradine; and c. treating ivabradine in situ with alcoholic hydrogen chloride in a suitable solvent to prepare its hydrochloride salt.
Another aspect of the present invention is to provide a novel form of ivabradine hydrochloride i.e. amorphous ivabradine hydrochloride.
One another aspect of the present invention provides a process for the preparation of amorphous ivabradine hydrochloride which comprises: a. hydrogenating the benzazepine intermediate of formula IV with palladium on carbon in glacial acetic acid under the atmosphere of hydrogen gas to get ivabradine;
Figure imgf000005_0004
Formula IV
b. treating ivabradine with a solution of organic acid in a suitable solvent to get ivabradine acid addition salt; c. optionally purifying the ivabradine acid addition salt; d. hydrolysing ivabradine acid addition salt with aqueous base in a suitable solvent; and e. treating the resulting ivabradine in situ with alcoholic hydrogen chloride in organic solvent.
In other aspect there is provided a process for the preparation of highly pure ivabradine hydrochloride which comprises: treating ivabradine with alcoholic hydrogen chloride in suitable solvent to prepare its hydrochloride salt.
One more another aspect of the present invention is to provide a process for the preparation of amorphous ivabradine hydrochloride which comprises: treating ivabradine with a solution of organic acid in a suitable solvent to get ivabradine acid addition salt; optionally purifying the ivabradine acid addition salt; hydrolysing ivabradine acid addition salt with base in a suitable solvent; and treating the resulting ivabradine with alcoholic hydrogen chloride in organic solvent.
Yet another aspect of the present invention is to provide a process for preparing amorphous ivabradine hydrochloride comprising: a. treating ivabradine hydrochloride with base in a suitable solvent; and b. treating the resulting ivabradine with alcoholic hydrogen chloride in organic solvent.
Still yet another aspect of the present invention is to provide a process for the preparation of amorphous ivabradine hydrochloride which comprises: a. dissolving ivabradine hydrochloride in a mixture of lower alkanol and ketone at ambient temperature; b. heating the solution to 40-50°C; c. distilling the solvent; and d. isolating amorphous ivabradine hydrochloride. In still yet another aspect of the present invention provides a process for preparing α crystalline form of ivabradine hydrochloride comprising the steps of: a. heating a solution ivabradine hydrochloride in suitable solvent; b. distilling off some of the solvent; c. filtering the reaction mixture to obtain ivabradine hydrochloride; and d. isolating α crystalline form of ivabradine hydrochloride. Ivabradine acid addition salts prepared in the present invention also forms the inventive part of the invention. Ivabradine oxalate is isolated as crystalline solid and is another inventive part of the invention.
BRIEF DESCRIPTION OF THE DRAWINGS Figure 1 is a powdered X-ray diffraction pattern for amorphous ivabradine hydrochloride.
Figure 2 is a powdered X-ray diffraction pattern for α crystalline form of ivabradine hydrochloride.
Figure 3 is a powdered X-ray diffraction pattern for ivabradine oxalate. Figure 4 is a DSC thermogram for ivabradine oxalate. DETAILED DESCRIPTION OF THE INVENTION
The instant invention relates to an efficient and industrially advantageous process for the preparation of highly pure ivabradine or a pharmaceutically acceptable salt and in particular ivabradine hydrochloride.
One aspect of the present invention relates to an improved process for the preparation of highly pure ivabradine hydrochloride by initially condensing methylamine derivative of formula II with benzazepine derivative of formula III to form benzazepine intermediate of formula IV in the presence of a base, in a polar aprotic or protic solvents. The base can be selected from alkali metal carbonates, bicarbonates and hydroxides and preferably potassium carbonate. The polar aprotic or protic solvent is selected from tetrahydrofuran, acetone, acetonitrile, dimethylformamide, dimethylsulfoxide, water, isopropanol, Ci-C4 linear aliphatic alcohols such as methanol, ethanol etc. and mixtures thereof. More preferably, the solvent is dimethylformamide or dimethylsulfoxide and most preferably the solvent is dimethylformamide. It is advantageous to use dimethylformamide during condensation reaction because reaction rate is faster and it takes only 2-3 hours for completion of reaction as compared to prior art processes wherein 18 hours are required in acetone. Reaction is conducted at 30-75°C and preferably at 50- 60°C. The completion of reaction is monitored by high performance liquid chromatography. After completion of the reaction, the reaction mass is cooled to ambient temperature and diluted with water. The product is extracted in organic solvent from aqueous layer and some impurities remain in the aqueous layer. The solvent can be selected from halogenated hydrocarbon such as methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform and aliphatic ester such as ethyl acetate and preferably methylene chloride is used. Thereafter, solvent is distilled off completely and the product is purified by acid base wash treatment. Specifically the residue is treated with hydrochloric acid in water and washed with solvent such as ethyl acetate, thereafter the aqueous layer is neutralized with base and the desired compound is extracted in organic solvent. The organic solvent can be selected from halogenated hydrocarbons and aliphatic esters as mentioned above and preferably ethyl acetate is used. The product is obtained in high purity and no chromatographic purification is required. It has also been found that during condensation process an unknown impurity has also been formed, which is not easily removed by using the prior art isolation process and hence decreases the purity of the condensed product. But during the process of present invention, it is observed that the said unknown impurity can be easily removed by extracting the desired product from the reaction mixture with halogenated solvents such as methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform. This further avoids the use of tedious chromatographic purification.
According to another aspect of the present invention, benzazepine intermediate of formula IV is most preferably prepared by condensing methylamine derivative of formula II with 7,8- dimethoxy-3-[3-iodopropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula III in demineralized water and in the presence of a base. The condensation reaction is carried out at 45-60°C preferably at 5O-55°C and it takes 10-20 hours for completion of reaction. The progress of reaction is monitored by high performance liquid chromatography (HPLC). The product is extracted in lower aliphatic ester solvent such as ethyl acetate. Ethyl acetate layer is further treated with aqueous acidic solution and the resulting layers are separated. The aqueous layer is treated with basic solution and the product is extracted in lower aliphatic ester solvent such as ethyl acetate. Ethyl acetate layer is removed by known methods such as evaporation, distillation with or without vacuum etc to get benzazepine intermediate of formula IV. The base is used in the condensation step can be selected from alkali metal carbonates, bicarbonates and hydroxides and preferably potassium carbonate. The intermediates II and III can be prepared by the methods reported in the prior art with minor modifications. Specifically the methyl amine derivative of Formula II is prepared by the reduction of l-cyano-4,5-dimethoxybenzocyclobutane of formula V
Figure imgf000008_0001
Formula V
using reducing agent such as borane complexes like borane dimethyl sulfide complex in tetrahydrofuran which is converted to acid addition salt by treatment with acid in suitable solvent. Particularly hydrochloride salt is prepared by treating the amino derivative with alcoholic hydrogen chloride; ethereal hydrogen chloride such as ethanol hydrogen chloride, isopropyl acetate hydrogen chloride, isopropyl ether hydrogen chloride etc.
Hydrochloric acid salt of the obtained amino intermediate is further condensed with ethyl chloroformate in the presence of a suitable base to prepare the corresponding amide. The resulting amide is reduced with lithium aluminium hydride in tetrahydrofuran to prepare racemic methyl amine intermediate of formula II. Racemic intermediate is further resolved with suitable resolving agent such as (d)-camphosulphonic acid to produce desired (+) isomer methyl amine of formula II which can optionally be used in oily form or can be isolated.
The said process is very useful during its application at large-scale production because borane dimethyl sulphide complex is stable at room temperature hence its storage and handing is not difficult during large scale production.
Specifically the benzazepine compound of formula III is prepared by the reaction of 7,8- dimethoxy-3-[3-chloropropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula VI with sodium iodide in acetone followed by its purification by slurry washing of the residue with acetone. The intermediates of formula V and VI are prepared by the methods reported in the literatures (T. Kametani et al, Tetrahedron 1973; vol. 29; pages 73-76 and Reiffer M. et al., J. Med. Chem.. 1990; vol 33 (5): 1496-1504).
The intermediate of formula V can also be prepared by the reaction of 6-bromovaretraldehyde with cyanoacetic acid in the presence of ammonium acetate and in solvents optionally selected from pyridine, toluene, benzene etc. or mixtures thereof. The isolated intermediate is further reduced with sodium borohydride in the presence of aqueous base. Generally bases are selected from sodium bicarbonate, sodium carbonate, potassium hydroxide, sodium hydroxide or mixtures thereof to get β-(2-bromo-4,5-dimethoxyphenyl)-α-cyanopropionic acid. The resulting acid upon decarboxylation in Λf,iV-dimethyl acetamide and subsequent reaction with sodium amide or potassium amide in liquid ammonia is converted to l-cyano-4,5- dimethoxybenzocyclobutane of formula V.
Furthermore, the intermediate of formula VI can also be prepared by the halogenation of 3,4- dimethoxyphenyl acetic acid with some halogenating agents such as thionyl chloride in chlorinated solvents such as methylene dichloride. The obtained chloro compound is further condensed with aminoacetaldehyde dimethyl acetal in the presence of a suitable base to prepare corresponding amide derivative. The ring closure of resulting amide into benzazepin moiety is carried out in presence of an acid, for example, hydrochloric acid, glacial acetic acid or mixtures thereof. Obtained benzazepin moiety is further alkylated with l-bromo-3-chloro-propane in presence of a suitable base such as potassium tertiary butoxide in an organic solvent to obtain 7,8-dimethoxy-3-[3-chloropropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula VI. The organic solvents can be selected from acetone, dimethylsulfoxide, dimethylformamide, etc. or mixtures thereof. Benzazepine intermediate of formula IV prepared by the processes of present invention is hydrogenated and converted into highly pure ivabradine or a pharmaceutically acceptable salt thereof.
Typically, the condensed product i.e. (S)-7,8-dimethoxy-3-{3 {N-[(4,5-dimethoxybenzocyclobut- l-yl)methyl]-N-(methyl)amino)propyl)-l,3-dihydro-2H-3-benzazepin-2-one of formula IV is converted to ivabradine hydrochloride. The compound of formula IV is catalytically hydrogenated using palladium on carbon catalyst in acetic acid under hydrogen pressure of 1-7 kg/cm . The hydrogenation reaction is conducted at ambient temperature and it takes 4-10 hours for completion of reaction, which is monitored by high performance liquid chromatography (HPLC). The catalyst is filtered out and the product is extracted in organic solvent from filtrate or acetic acid is removed by distillation from the filtrate. The organic solvent consists of methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform. The filtrate is further treated with dilute hydrochloric acid and extracted with same organic solvent.
Thereafter the combined extracts were distilled and the resulting residue is treated with dilute hydrochloric acid. The aqueous layer is washed with organic solvent such as ethyl acetate to remove impurities and neutralized with base like aqueous sodium hydroxide. Thereafter the desired compound is extracted in organic solvent. The organic solvent can be selected from above mentioned solvents such as halogenated hydrocarbon and aliphatic esters and preferably ethyl acetate is used. Optionally the ivabradine is isolated; otherwise organic layer itself is treated with alcoholic hydrogen chloride to prepare highly pure ivabradine hydrochloride. It is advantageous to dry the organic layer using drying agent such as sodium sulfate or the like before adding alcoholic hydrogen chloride.
Preferably, ivabradine of formula I is converted into pharmaceutically acceptable acid addition salts using alcoholic acid mixture. Particularly the hydrochloride salt preparation is carried out using alcoholic hydrogen chloride. In general, a solution of alcoholic hydrogen chloride is prepared by purging dry hydrogen chloride in alcohol by following the methods reported in prior art. The percentage of hydrogen chloride in alcohol is preferably selected between 10-25%. The alcohol used in the solution of alcohol-hydrogen chloride is selected from C1-C4 branched or linear aliphatic alcohols and more preferably the solvent is methanol, ethanol, n-butanol or isopropanol and most preferably the solvent is methanol and isopropanol. The precipitated ivabradine hydrochloride is isolated in high yield and purity of greater than 99.0% area by HPLC. XRD pattern shows that material is amorphous in nature, substantially as depicted in Figure 1.
Amorphous Ivabradine hydrochloride is novel and forms one aspect of the present invention. Amorphous ivabradine hydrochloride is further characterized by a differential scanning calorimetry ("DSC") thermogram, which shows one endothermic peak around 194 °C due to melting.
Another aspect of the present invention relates to the preparation of highly pure amorphous ivabradine hydrochloride from ivabradine through ivabradine acid addition salts. Specifically the ivabradine is treated with a solution of organic acid in solvent selected from lower aliphatic ketone such as acetone; ester such as ethyl acetate and nitrile such as acetonitrile to prepare ivabradine acid addition salt.
The organic acid can be selected from acetic acid, propionic acid, maleic acid, fumaric acid, tartaric acid, oxalic acid, citric acid, benzoic acid, methanesulphonic acid, isethionic acid, benzenesulphonic acid, toluenesulphonic acid and the like. Preferably the acid is selected from oxalic acid, citric acid, methanesulphonic acid, benzenesulphonic acid, toluenesulphonic acid and most preferably the acid is oxalic acid.
Particularly the ivabradine oxalate is prepared by treating ivabradine with oxalic acid in acetone and reaction mass is stirred at ambient temperature for sufficient tine to prepare the oxalate salt. The oxalate salt is isolated by filtration and optionally recrystallized in acetonitrile to isolate pure ivabradine oxalate. The ivabradine oxalate is isolated as crystalline solid and may be characterized by at least one of Karl Fisher or TGA, X-Ray power diffraction (XRD), or differential scan calorimetry (DSC).
Crystalline ivabradine oxalate is characterized by powdered X-ray diffraction patterns having peaks at about 2.04, 2.13, 4.26, 7.06, 8.02, 8.53, 9.32, 10.91, 13.63, 15.07, 16.11, 16.44, 17.48, 18.37, 19.32, 20.38, 20.94, 21.95, 23.61, 24.26, 27.54 and 33.07 degrees two theta, substantially as depicted in Figure 3.
Crystalline ivabradine oxalate is further characterized by a differential scanning calorimetry ("DSC") thermogram, which shows one endothermic peak around 110°C due to melting, substantially as depicted in Figure 4.
X-ray diffraction of amorphous ivabradine hydrochloride and crystalline ivabradine oxalate are measured on a PANalytical X' Pert Pro diffractometer with Cu radiation and expressed in terms of two-theta, d-spacings and relative intensities. One of the ordinary skills in the art understands that experimental differences may arise due to differences in instrumentation, sample preparation or other factors. DSC analysis was performed using a Mettler Toledo 822 Star6. The crucible was crimped and punched prior to analysis. The weight of the samples was about 4-6 mg; the samples were scanned at a rate of 5 °C/min from 30 °C to 250 °C. The oven was constantly purged with nitrogen gas at a flow rate of 80 ml/min. Standard 40 μl aluminum crucibles covered by lids with one hole were used.
It is advantageous to purify the acid addition salt of ivabradine by known methods such as crystallization or slurring in suitable solvent to remove the unwanted impurities. Preferably, the isolated acid addition salt of ivabradine is recrystallized in a suitable organic solvent such as acetonitrile
Acid addition salt of ivabradine is hydrolyzed with a suitable base in demineralized water to get ivabradine. The base can be selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate and preferably sodium hydroxide is used. After complete hydrolysis, the desired compound is extracted in organic solvent. The organic solvent can be selected from halogenated hydrocarbon and aliphatic esters and preferably ethyl acetate is used. Ethyl acetate is distilled out to isolate the ivabradine as oil. Crude ivabradine is further dissolved in a suitable organic solvent such as acetone, ethyl acetate preferably in acetone. The pH of the resulting clear solution is adjusted to 1.0 to 2.0 with alcoholic hydrogen chloride and stirred for 30 to 60 minutes to get highly pure amorphous ivabradine hydrochloride. It is advantageous to dry the organic layer using drying agent such as sodium sulfate or the like before adding alcoholic hydrogen chloride.
Amorphous ivabradine hydrochloride is isolated by removing the solvent from the reaction mixture by known methods such as evaporation, distillation with or without vacuum etc.
Optionally the amorphous ivabradine hydrochloride is further stirred for 30 to 60 minutes in a suitable organic solvent such as n-heptane, n-hexane and cyclohexane then filtered and washed with same organic solvent to get highly pure amorphous ivabradine hydrochloride.
In yet another aspect of the present invention is provided a process for the preparation of amorphous ivabradine hydrochloride by dissolving ivabradine hydrochloride in a mixture of lower alkanol and ketone at ambient temperature and further heated to 40-50°C, distilling out the solvent under vacuum, isolating amorphous ivabradine hydrochloride.
The lower alkanol can be selected from methanol, ethanol, propanol, isopropanol and preferably methanol is used. The ketone can be selected from acetone, methyl ethyl ketone, methyl isobutyl ketone and preferably acetone is used. Mixture of lower alkanol and ketone is used in a ratio of 1: 2-6 (v/v) more preferably 1 :3 (v/v) and most preferably 1:2 (v/v). Specifically ivabradine hydrochloride is dissolved in a mixture of methanol and acetone by simple stirring at room temperature without using prior heating. Amorphous ivabradine hydrochloride is isolated by removing the solvent from the reaction mixture by known methods such as evaporation, distillation with or without vacuum etc. Alternatively the isolation of highly pure amorphous ivabradine hydrochloride is carried out by stirring the amorphous ivabradine hydrochloride in a suitable organic solvent such as n-heptane, n-hexane and cyclohexane for about 30 to 60 minutes followed by filtering and washingd with same organic solvent to get highly pure amorphous ivabradine hydrochloride. In yet another aspect of the present invention amorphous ivabradine hydrochloride can also be prepared from α crystalline form of ivabradine hydrochloride. Specifically the crystalline ivabradine hydrochloride is treated with suitable base and in a suitable solvent followed by regeneration of ivabradine hydrochloride from the solution of isopropyl alcohol/hydrogen chloride to get amorphous ivabradine hydrochloride. The base can be selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate. The solvent can be selected from ethyl acetate, isopropyl acetate, methyl isobutyl ketone and acetone.
In still yet another aspect of the present invention the α crystalline form of ivabradine hydrochloride can also be prepared by recrystallization of ivabradine hydrochloride in suitable organic solvent such as acetonitrile, followed by addition of lower aliphatic ketone, ester, straight branched or cyclic ethers or mixtures thereof heat the mixture, removed solvents and recovered the α crystalline form of ivabradine hydrochloride.
In still yet another aspect of the present invention the α crystalline form of ivabradine hydrochloride can also be prepared from amorphous ivabradine in suitable organic solvent such as lower aliphatic ketone, ester, straight branched or cyclic ethers or nitriles or mixtures thereof. The lower aliphatic ketonic solvents can be selected from methyl isobutyl ketone, acetone or the like. The esters can be selected from ethyl acetate and isopropyl acetate. The ether can be selected from isopropyl ether, tetrahydrofuran and the like. The nitrile can be acetonitrile and the like. Ivabradine hydrochloride is taken in suitable solvent and heated at 60-90°C for sufficient time to transform to α crystalline form of ivabradine hydrochloride.
Having described the invention with reference to certain preferred embodiments, other embodiments will become apparent to one skilled in the art from consideration of the specification. The invention is further defined by reference to the following examples describing in detail the preparation of the product and methods of use of the invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the scope of the invention.
EXAMPLES
Example 1: Preparation of Ivabradine hydrochloride Stepl: Preparation of (S)-7,8-dimethoxy-3-{3-{N-f(4,5-dimethoxybenzocvclobut-l-yl) methyll-N-(methvDamino)propyl)- l,3-dihydro-2H-3-benzazepin-2-one
To a mixture of (S)-N-[(4,5-dimethoxybenzocyclobut-l-yl)-methyl]-N-(methyl)amine (42g) and N,N-dimethylformamide (220ml) was charged 7,8-dimethoxy-3-[3-iodopropyl]-l,3-dihydro-2H- 3-benzazepin-2-one (75g) and potassium carbonate (42g) at room temperature. The reaction mixture was heated and stirred the reaction mass at 50-55 °C for 2 hours and the completion of reaction was monitored by HPLC/TLC. After completion of reaction, reaction mass was cooled to 25-30 °C and diluted with dimineralized water (1000ml). The reaction mixture was extracted with methylene dichloride (400ml x 200ml) and the layers were separated. Methylene chloride was distilled off completely. To the residue, dimineralized water (200ml) and hydrochloric acid (50ml) were added and the aqueous solution is washed with ethyl acetate (200ml x 3). The layers were separated and to the aqueous layer 50 % (w/v) sodium hydroxide solution (120ml) was added at 25-30 °C. The aqueous layer was extracted with ethyl acetate (400ml + 200 ml) and the combined ethyl acetate layer was washed with 5 %( w/v) sodium hydroxide solution (300ml). Ethyl acetate layer was dried over anhydrous sodium sulfate and then ethyl acetate was distilled out completely under vacuum to get the title compound.
Step 2:Preparation of (S)-7,8-dimethoxy-3-{3-{Ν-[(4,5-dimethoxybenzocyclobut-l-vπmethyl 1-N-(methyl)amino)propyl)-l,3..4,5-tetrahvdro-2H-3-benzazepin-2-one hydrochloride
Benzazepine compound (85g) obtained in step 1 was taken in acetic acid (700ml), and was hydrogenated under a hydrogen pressure (1-2 kg) at room temperature in the presence of Pd/C (10%, 7Og). Further hydrogenation was continued with 6-7 kg/cm2 hydrogen gas pressure at 20 °C for 6-8 hours. After completion of hydrogenation (monitored by HPLC), the catalyst was filtered off and catalyst was washed with water (800ml). The filtrate was then extracted with methylene chloride (700ml) and to the aqueous layer hydrochloric acid solution (50ml) was added. The aqueous layer was again extracted with methylene dichloride (300ml x 3). The combined organic layer was distilled off and to the residue dimineralized water (400ml) and hydrochloric acid solution (90 ml) were charged followed by ethyl acetate (400ml). The reaction mixture was stirred at 30-35 °C for half an hour and the layers were separated. The aqueous layer was again washed with ethyl acetate (500ml). Thereafter aqueous layer was treated with 50 % (w/v) sodium hydroxide solution (150ml). The aqueous layer was extracted with ethyl acetate (400ml + 250ml) and combined ethyl acetate layer was washed with 5% (w/v) sodium hydroxide solution (400ml). Ethyl acetate layer was dried over anhydrous sodium sulfate and then solvent was distilled out completely. The residue was taken in ethyl acetate (400ml) and to this isopropyl alcohol-hydrogen chloride (50ml) was added slowly and was stirred for 4-5 hours. The product obtained was filtered, washed with ethyl acetate (85ml) and dried at 55-60 °C to obtain the title compound in amorphous form having purity 98.5% area by HPLC.
Example 2: Preparation of benzazepine intermediate of formula IV
7,8-Dimethoxy-3-[3-iodopropyl]-l,3-dihydro-2H-3-benzazepin-2-one (38g) and potassium carbonate (6Og) were added to a mixture of (S)-N-[(4,5-dimethoxybenzocyclobut-l-yl)-methyl]- 7V-(methyl)amine (2Og) and demineralized water (100ml) at room temperature. The reaction mixture was heated and stirred at 50-55 °C for 12-16 hours. After completion of reaction, reaction mass was cooled to 25-30 0C and the product is extracted in ethyl acetate (100ml). The aqueous layer was further extracted with ethyl acetate (60ml). Combined ethyl acetate layers was acidified with aqueous hydrochloric acid and stirred. The layers were separated and pH of the aqueous layer was adjusted to 10.5-12.5 with aqueous sodium hydroxide solution. The aqueous layer is extracted with ethyl acetate (140ml + 60ml). Ethyl acetate was distilled out completely under vacuum to get the title compound.
Example 3: Preparation of amorphous ivabradine hydrochloride Benzazepine intermediate of formula IV (85g) was taken in acetic acid (700ml), and was hydrogenated under a hydrogen pressure (1-2 kg) at room temperature in the presence of Pd/C (10%, 7Og). Further hydrogenation was continued with 6-7 kg/cm2 hydrogen gas pressure at 20 °C for 6-8 hours. After completion of hydrogenation (monitored by HPLC), the catalyst was filtered off and acetic acid was removed by distillation. To the residue demineralized water (360ml) and hydrochloric acid (40ml) were added followed by addition of ethyl acetate (200ml). The resulting mixture was stirred and the layers were separated. The aqueous layer was washed with ethyl acetate (100ml). The pH of the aqueous layer was adjusted to 10.5-12.5 with aqueous sodium hydroxide solution and product was extracted in ethyl acetate (400ml). Ethyl acetate layer was dried over anhydrous sodium sulfate and then solvent was distilled out completely. The residue was taken in ethyl acetate (1020ml) and to this oxalic acid (34g) in acetone (68ml) was added slowly and was stirred for 3-4 hours at ambient temperature. The ivabradine oxalate obtained was filtered and recrystallized in acetonitrile. Ivabradine oxalate was taken in demineralized water (340ml) and pH of the reaction mixture was adjusted to 10-12 with aqueous sodium hydroxide solution and stirred. The resulting mixture is then extracted with ethyl acetate (340ml). Ethyl acetate was distilled out completely. Thereafter, the residue was taken in acetone (220ml) and to this methanol-hydrogen chloride (30-35ml) was added slowly and was stirred for 30 minutes. The solvent was removed by distillation under reduced pressure. The amorphous product, thus obtained, was further stirred with n-heptane for 30-40 minutes, filtered, washed with n-heptane (50ml) and dried at 40-45 0C to obtain amorphous ivabradine hydrochloride having purity 99.9% area by High performance liquid chromatography (HPLC). XRD pattern showed that product was amorphous in nature and same as depicted in figure 1.
Example 4: Preparation of amorphous ivabradine hydrochloride Step-1: Preparation of ivabradine oxalate Ivabradine (44g) was dissolved in ethyl acetate (700ml) and to this oxalic acid (22g) in acetone (50ml) was added slowly and stirred for 3-4 hours at ambient temperature. The ivabradine oxalate, thus obtained was filtered, washed with ethyl acetate (100ml) and recrystallized in acetonitrile (350ml). XRD pattern shows that isolated ivabradine oxalate was crystalline in nature and depicted in Figure 2. Step-2: Preparation of amorphous ivabradine hydrochloride
Ivabradine oxalate was taken in demineralized water (200ml) and to this aqueous sodium hydroxide solution (100ml) was added and stirred. The resulting mixture was extracted with ethyl acetate (250ml). Ethyl acetate layer was dried over anhydrous sodium sulfate and then solvent was distilled out completely. The resulting residue was taken in acetone (100ml) and to this methanol-hydrogen chloride (7ml) was added slowly and was stirred for 30 minutes. Thereafter the solvent was removed by distillation under reduced pressure. To the amorphous product, n-heptane (100ml) was added and stirred for 30 minutes, filtered, washed with n- heptane (50ml) and dried at 40-45 °C to obtain the title compound.
Example 5: Preparation of amorphous ivabradine hydrochloride Ivabradine hydrochloride (2Og) was dissolved in stirred mixture of acetone (100ml) and methanol (50ml) at ambient temperature. The solution was heated to 50 °C and the solvent was distilled off under reduced pressure. The amorphous product, thus obtained, was stirred with n- heptane (100ml). The reaction mixture was filtered, washed with n-heptane and dried at 40-45 °C under vacuum to obtain the title compound. Example 6: Preparation of amorphous ivabradine hydrochloride α- Crystalline form of ivabradine hydrochloride (6 gm) was taken in water (30 ml) and basified by sodium hydroxide solution (50 %). Ivabradine, thus formed, was extracted with ethyl acetate (50 ml) and was dried over anhydrous sodium sulfate. Solvent was distilled off. Residue was taken in ethyl acetate (30ml) and isopropyl alcohol hydrogen chloride (5ml) was added slowly and was stirred for 2 hours. Product thus obtained was filtered, washed with ethyl acetate (6 ml) and dried at 55-60 0C to obtained amorphous ivabradine hydrochloride having purity 99.93 % area by HPLC.
Example 7: Preparation of α crystalline form of ivabradine hydrochloride
Ivabradine hydrochloride (47g) was taken in acetonitrile (940ml) and heated to 80±2 °C for 30 minutes till clear solution. Thereafter, half of the acetonitrile was distilled off and the reaction mass was cooled, filtered and washed with acetonitrile to get wet cake of the product. Obtained wet cake was further dissolved in ethyl acetate (611ml) at room temperature then heated the mixture to 75-80 0C and maintained for 60 minutes. The reaction mixture was concentrated by distillation of about one third of ethyl acetate. The reaction mass was cooled, filtered, washed with ethyl acetate and dried under vacuum to obtain the title compound.
Example 8: Preparation of α crystalline form of ivabradine hydrochloride from amorphous form
Amorphous ivabradine hydrochloride (4 gm) was taken in ethyl acetate (60 ml) and heated to reflux for 30 minutes. Thereafter one third of ethyl acetate was distilled off and the reaction mass was cooled to 25-30 °C. The product obtained was filtered and dried to obtain the title compound having purity 99.89 % area by HPLC. Example 9: Preparation of α crystalline form of ivabradine hydrochloride
Ivabradine hydrochloride (2 gm) was taken in acetone (200 ml) and heated to reflux till clear solution, suspended material was filtered off. Thereafter 60% of acetone was distilled off and reaction mass was cooled to room temperature. The product was filtered, washed with acetone (10 ml) and dried to obtain the title compound having purity 99.73 % area by HPLC.

Claims

WE CLAIM
1. A process for the preparation of highly pure ivabradine hydrochloride of formula I,
Figure imgf000018_0001
Formula I
comprising the steps of:
a. condensing methylamine of formula II,
Figure imgf000018_0002
Formula II
with 7,8-dimethoxy-3-[3-iodopropyl]-l,3-dihydro-2H-3-benzazepin-2-one of formula III
Figure imgf000018_0003
Formula III
in the presence of a base in polar solvent to prepare benzazepine intermediate of formula IV;
Figure imgf000018_0004
Formula IV
b. hydrogenating the benzazepine intermediate of formula IV with palladium on carbon in glacial acetic acid under the atmosphere of hydrogen to get ivabradine, and
c. converting ivabradine in situ to its hydrochloride salt using alcoholic hydrogen chloride in suitable solvent.
2. The process according to claim 1, wherein in step a), base is alkali metal carbonates, bicarbonates and hydroxides.
3. The process according to claim 1, wherein in step a), base is potassium carbonate.
4. The process according to claim 1, wherein in step a), polar solvent is selected from water, tetrahydrofuran, acetone, acetonitrile, dimethylformamide, dimethylsulfoxide, isopropanol, C]-C4 linear aliphatic alcohols such as methanol, ethanol.
5. The process according to claim 1 , wherein in step c, alcohol in alcoholic hydrogen chloride, is selected from Ci-C4 branched or linear aliphatic alcohols such as n-butanol or isopropanol.
6. The process according to claim 1 , wherein in step c, the solvent is selected from halogenated hydrocarbon and aliphatic esters such as methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform, ethyl acetate and methyl acetate.
7. A process for the preparation of amorphous ivabradine hydrochloride comprising the steps of:
a) hydrogenating the benzazepine intermediate of formula IV with palladium on carbon in glacial acetic acid under the atmosphere of hydrogen gas to form ivabradine;
Figure imgf000019_0001
Formula IV
b) treating ivabradine with a solution of organic acid in a suitable solvent to obtain ivabradine acid addition salt;
c) optionally purifying the ivabradine acid addition salt;
d) hydrolysing ivabradine acid addition salt with a base;
e) treating the resulting ivabradine in situ with alcoholic hydrogen chloride in organic solvent; and
f) isolating amorphous ivabradine hydrochloride therefrom.
8. The process according to claim 7, wherein in step b, organic acid is selected from acetic acid, propionic acid, maleic acid, fumaric acid, tartaric acid, oxalic acid, citric acid, benzoic acid, methanesulphonic acid, isethionic acid, benzenesulphonic acid and toluene sulphonic acid.
9. The process according to claim 7, wherein in step b, solvent is selected from lower aliphatic ketone such as acetone; ester such as ethyl acetate and nitrile such as acetonitrile.
10. The process according to claim 7, wherein in step d, base is selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate.
11. The process according to claim 7, wherein in step e, alcohol in alcoholic hydrogen chloride, is selected from Ci-C4 branched or linear aliphatic alcohols such as n-butanol or isopropanol.
12. The process according to claim 7, wherein in step e, the solvent is selected from methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform, ethyl acetate, methyl acetate and acetone.
13. A process for the preparation of amorphous ivabradine hydrochloride comprising the steps of:
a) treating ivabradine with a solution of organic acid in a suitable solvent to get ivabradine acid addition salt;
b) optionally purifying the ivabradine acid addition salt;
c) hydrolysing ivabradine acid addition salt with a base;
d) treating the resulting ivabradine with alcoholic hydrogen chloride in organic solvent; and
e) isolating amorphous ivabradine hydrochloride.
14. The process according to claim 13, wherein in step a, the organic acid is selected from acetic acid, propionic acid, maleic acid, fumaric acid, tartaric acid, oxalic acid, citric acid, benzoic acid, methanesulphonic acid, isethionic acid, benzenesulphonic acid and toluene sulphonic acid.
15. The process according to claim 13, wherein in step a, solvent is selected from lower aliphatic ketone such as acetone; ester such as ethyl acetate and nitrile such as acetonitrile.
16. The process according to claim 13, wherein in step b, the solvent is acetonitrile.
17. The process according to claim 13, wherein in step c, base is selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate.
18. The process according to claim 13, wherein in step d, alcohol in alcoholic hydrogen chloride, is selected from Ci-C4 branched or linear aliphatic alcohols such as n-butanol or isopropanol.
19. The process according to claim 13, wherein in step d, the solvent is selected from methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform, ethyl acetate, methyl acetate and acetone.
20. A process for the preparation of amorphous ivabradine hydrochloride comprising the steps of:
a. dissolving ivabradine hydrochloride in a mixture of lower alkanol and ketone at ambient temperature;
b. heating the solution to 40-50°C;
c. distilling out the solvent; and
d. isolating amorphous ivabradine hydrochloride.
21. The process according to claim 20, wherein lower alkanol and ketone are selected from methanol, ethanol, propanol, isopropanol, acetone, methyl ethyl ketone and methyl isobutyl ketone.
22. A process for the preparation of amorphous ivabradine hydrochloride comprising the steps of:
a. treating ivabradine hydrochloride with a base in a suitable solvent, and
b. treating the resulting ivabradine with alcoholic hydrogen chloride in an organic solvent.
23. The process according to claim 22, wherein in step a, the solvent is selected from ethyl acetate, isopropyl acetate, methyl isobutyl ketone and acetone.
24. The process according to claim 22, wherein in step a, base is selected from sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium bicarbonate and potassium bicarbonate.
25. The process according to claim 22, wherein in step b, alcoholic hydrogen chloride, is isopropanolic hydrogen chloride.
26. The process according to claim 22, wherein in step b, the solvent is selected from halogenated hydrocarbon and aliphatic esters such as methylene dichloride, ethylene dichloride, carbon tetrachloride, chloroform, ethyl acetate and methyl acetate.
27. A process for the conversion of amorphous ivabradine hydrochloride to α crystalline form of ivabradine hydrochloride comprising the steps of: a. heating amorphous ivabradine hydrochloride in a suitable organic solvent;
b. distilling off some of the solvent;
c. optionally repeating the steps a and b; and
d. isolating α crystalline form of ivabradine hydrochloride.
28. The process according to claim 27, wherein the organic solvent is selected from methyl isobutyl ketone, acetone, ethyl acetate and isopropyl acetate, tetrahydrofuran, isopropyl ether and acetonitrile.
29. Amorphous ivabradine hydrochloride.
30. Crystalline ivabradine oxalate characterized by at least one of the following:
a. powder X-ray diffraction peaks at about 2.04, 2.13, 4.26, 7.06, 8.02, 8.53, 9.32, 10.91,
13.63, 15.07, 16.11, 16.44, 17.48, 18.37, 19.32, 20.38, 20.94, 21.95, 23.61, 24.26, 27.54 and 33.07 degrees 2Θ; or
b. differential scanning calorimetry thermogram, which shows one endothermic peak around 110°C.
PCT/IN2008/000341 2007-05-30 2008-05-29 Process for the preparation of ivabradine hydrochloride and polymorph thereof WO2008146308A2 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2010509952A JP5632279B2 (en) 2007-05-30 2008-05-29 Preparation method and polymorph of ivabradine hydrochloride
RU2009149375/04A RU2473544C2 (en) 2007-05-30 2008-05-29 Method of producing ivabradine hydrochloride and polymorphs thereof
US12/602,348 US8212026B2 (en) 2007-05-30 2008-05-29 Process for the preparation of ivabradine hydrochloride and polymorph thereof
KR1020097026828A KR101478855B1 (en) 2007-05-30 2008-05-29 Process for the preparation of ivabradine hydrochloride and polymorph thereof
EP08763748A EP2162438A4 (en) 2007-05-30 2008-05-29 Process for the preparation of ivabradine hydrochloride and polymorph thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN1157/DEL/2007 2007-05-30
IN1157DE2007 2007-05-30
IN1950DE2007 2007-09-13
IN1950/DEL/2007 2007-09-13

Publications (3)

Publication Number Publication Date
WO2008146308A2 true WO2008146308A2 (en) 2008-12-04
WO2008146308A9 WO2008146308A9 (en) 2009-01-15
WO2008146308A3 WO2008146308A3 (en) 2010-03-11

Family

ID=40075646

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2008/000341 WO2008146308A2 (en) 2007-05-30 2008-05-29 Process for the preparation of ivabradine hydrochloride and polymorph thereof

Country Status (9)

Country Link
US (1) US8212026B2 (en)
EP (2) EP2471780B1 (en)
JP (1) JP5632279B2 (en)
KR (1) KR101478855B1 (en)
AR (1) AR066810A1 (en)
ES (1) ES2528026T3 (en)
PT (1) PT2471780E (en)
RU (1) RU2473544C2 (en)
WO (1) WO2008146308A2 (en)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2940287A1 (en) * 2008-12-24 2010-06-25 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
WO2011098582A2 (en) 2010-02-12 2011-08-18 Krka, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
FR2956401A1 (en) * 2010-02-17 2011-08-19 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
WO2011138625A1 (en) 2010-05-07 2011-11-10 Richter Gedeon Nyrt. Industrial process for the synthesis of ivabradine salts
WO2011157722A2 (en) 2010-06-14 2011-12-22 Ratiopharm Gmbh Solid ivabradine-containing composition
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
JP2012515141A (en) * 2009-01-13 2012-07-05 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ivabradine sulfate and method for producing the same type I crystal
KR101166632B1 (en) 2009-03-31 2012-07-19 르 라보레또레 쎄르비에르 New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
KR101166630B1 (en) 2009-03-31 2012-07-19 르 라보레또레 쎄르비에르 New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
CN102731400A (en) * 2011-04-11 2012-10-17 山东新时代药业有限公司 Novel ivabradine hydrochloride crystal form and its preparation method and use in preparation of pharmaceutical composition
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
JP2013505225A (en) * 2009-09-18 2013-02-14 レ ラボラトワール セルヴィエ A novel method for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acids
CN103012269A (en) * 2013-01-05 2013-04-03 江苏宇田生物医药科技有限公司 Novel ivabradine hydrochloride crystal form C and preparation method thereof
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
WO2013102919A1 (en) 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
WO2014020534A1 (en) * 2012-07-30 2014-02-06 Biocon Limited Ivabradine hydrochloride and the processes for preparation thereof
WO2014102827A1 (en) * 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ivabradine
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130684A1 (en) * 2013-04-24 2014-10-25 Chemo Res S L NEW POLIMORFO OF IVABRADINA CHLORIDRATE AND METHOD FOR ITS PREPARATION
ITMI20130830A1 (en) * 2013-05-22 2014-11-23 Laboratorio Chimico Int Spa PROCEDURE FOR THE PREPARATION OF IVABRADINA
CN104230808A (en) * 2014-08-22 2014-12-24 苏州亚宝药物研发有限公司 Amorphous ivabradine hydrochloride, and preparation method and application thereof
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
EA020735B1 (en) * 2011-02-14 2015-01-30 Ле Лаборатуар Сервье New method for synthesising ivabradine and pharmaceutically acceptable acid addition salts thereof
CN104447553A (en) * 2013-09-22 2015-03-25 广东众生药业股份有限公司 Preparation method for ivabradine and intermediate thereof
WO2015022702A3 (en) * 2013-08-10 2015-04-09 Ind-Swift Laboratories Limited Process for preparation of 4,5-dimethoxybenzene derivatives and use in the synthesis of ivabradine and salts thereof
WO2015048937A1 (en) 2013-10-02 2015-04-09 Zentiva, K.S. A solid form of ivabradine hydrochloride and (s)-mandelic acid and a pharmaceutical composition thereof
WO2015101072A1 (en) * 2014-01-06 2015-07-09 北京莱瑞森医药科技有限公司 S crystal form of ivabradine hydrochloride, and preparation method and pharmaceutical composition thereof
CZ305436B6 (en) * 2014-07-10 2015-09-16 Zentiva, K.S. Solid form of ivabradine hydrochloride and (R)-mandelic acid and pharmaceutical composition thereof
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
EA026510B1 (en) * 2011-12-20 2017-04-28 Ле Лаборатуар Сервье New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
EP3280399A1 (en) * 2015-04-10 2018-02-14 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising ivabradine oxalate
CN107698508A (en) * 2017-10-24 2018-02-16 重庆东得医药科技有限公司 A kind of synthetic method of dehydrogenation Ivabradine
EP3366281A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013064427A1 (en) * 2011-11-04 2013-05-10 Synthon Bv A process for making crystalline delta-form of ivabradine hydrochloride
FR2984320B1 (en) * 2011-12-20 2013-11-29 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
WO2013150544A2 (en) * 2012-04-02 2013-10-10 Hetero Research Foundation Ivabradine hydrochloride solid dispersion
WO2014080259A1 (en) * 2012-11-21 2014-05-30 Enaltec Labs Pvt. Ltd. Novel polymorphic forms of alcaftadine
ITMI20130416A1 (en) * 2013-03-19 2014-09-20 Chemo Res S L NEW POLIMORFO OF IVABRADINA CHLORIDRATE AND METHOD FOR ITS PREPARATION
ES2773502T5 (en) * 2013-03-19 2023-11-30 Chemo Res S L New polymorph of ivabradine hydrochloride and method for its preparation
CN107056706B (en) * 2015-12-21 2020-05-05 江苏恒瑞医药股份有限公司 Method for preparing ivabradine hydrochloride α crystal form
GB201621771D0 (en) * 2016-12-20 2017-02-01 Biogena (A P I) Ltd New salts of compounds and uses thereof
CN108424390A (en) * 2018-01-25 2018-08-21 扬子江药业集团北京海燕药业有限公司 A kind of preparation method of high-purity hydrochloric acid Ivabradine
US20240122939A1 (en) * 2021-02-26 2024-04-18 The Regents Of The University Of California Therapies for the treatment of diseases and disorders associated with abnormal expression of cdkl5 gene

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2663328B1 (en) 1990-06-14 1994-08-05 Sanofi Sa DERIVATIVES OF HEXAHYDROAZEPINES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FR2681862B1 (en) * 1991-09-27 1993-11-12 Adir Cie NOVELS (BENZOCYCLOALKYL) ALKYLAMINES, THEIR PREPARATION PROCESS, AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
JP3968602B2 (en) * 1996-05-30 2007-08-29 旭硝子株式会社 Method for producing amorphous paroxetine hydrochloride
FR2868777B1 (en) * 2004-04-13 2006-05-26 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2868776B1 (en) 2004-04-13 2008-04-18 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF 1,3-DIHYDRO-2H-3-BENZAZEPIN-2-ONE DERIVATIVES AND THE APPLICATION TO THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2868775B1 (en) 2004-04-13 2008-04-11 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF 1,3,4,5-TETRAHYDRO-2H-3-BENZAZEPIN-2-ONE DERIVATIVES AND THE APPLICATION TO THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2870537A1 (en) 2004-05-19 2005-11-25 Servier Lab NOVEL PROCESS FOR SYNTHESIZING (1S) -4,5-DIMETHOXY-1- (METHYL AMINOMETHYL) BENZOCYCLOBUTANE AND ITS ADDITION SALTS AND APPLICATION TO THE SYNTHESIS OF IVABRADINE AND ITS ADDITION SALTS PHARMACEUTICALLY ACCEPTABLE ACID
ATE512961T1 (en) * 2004-07-30 2011-07-15 Torrent Pharmaceuticals Ltd AMORPHIC NEBIVOLOL HYDROCHLORIDE AND ITS PRODUCTION
FR2882553B1 (en) 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE BETA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882556B1 (en) 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE GAMMA D FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882555B1 (en) 2005-02-28 2007-05-04 Servier Lab CRYSTALLINE GAMMA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2882554B1 (en) 2005-02-28 2007-05-04 Servier Lab IVABRADINE HYDROCHLORIDE BETA D-CRYSTALLINE FORM, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2891827B1 (en) 2005-10-11 2007-12-28 Servier Lab CRYSTALLINE DELTAD FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
FR2891826B1 (en) 2005-10-11 2007-12-28 Servier Lab CRYSTALLINE FORM 6 OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EP2460797A3 (en) 2006-11-30 2012-12-05 Cadila Healthcare Limited Process for preparation of ivabradine hydrochloride
WO2008125006A1 (en) 2007-04-12 2008-10-23 Utopharm (Shanghai) Co., Ltd Preparation processes for ivabradine hydrochloride and its stable crystalline form
SI22750A (en) 2008-04-07 2009-10-31 Krka D.D. Ivabradin hydrobromide
FR2932800B1 (en) * 2008-06-20 2015-02-20 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF 7,8-DIMETHOXY-1,3-DIHYDRO-2H-3-BENZAZEPIN-2-ONE AND THE APPLICATION TO THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
WO2009158005A1 (en) 2008-06-27 2009-12-30 Concert Pharmaceuticals, Inc. Benzazepinone compounds
FR2933975B1 (en) 2008-07-17 2011-02-18 Servier Lab NOVEL PROCESS FOR THE PREPARATION OF FUNCTIONALIZED BENZOCYCLOBUTENES, AND APPLICATION TO THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2935381B1 (en) 2008-08-29 2010-12-17 Servier Lab NOVEL METHOD FOR THE RESOLUTION OF ENANTIOMERES OF (3,4-DIMETHOXY-BICYCLOO-4.2.0-OCTA-1,3,5-TRIEN-7-YL) NITRILE AND APPLICATION TO THE SYNTHESIS OF IVABRADINE
CN102264689B (en) 2008-12-22 2014-12-31 新梅斯托克尔卡公司 Process for preparation of ivabradine
FR2940287B1 (en) 2008-12-24 2010-12-24 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
CN101774969B (en) 2009-01-13 2012-07-04 江苏恒瑞医药股份有限公司 Ivabradine sulfate and method for preparing type I crystal thereof
FR2941695B1 (en) 2009-02-04 2011-02-18 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2943667B1 (en) * 2009-03-31 2011-05-06 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2943668B1 (en) * 2009-03-31 2011-05-06 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
FR2950343B1 (en) 2009-09-18 2011-11-18 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of EP2162438A4 *

Cited By (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA016405B1 (en) * 2008-12-24 2012-04-30 Ле Лаборатуар Сервье Method for synthesising ivabradine and its added salts with a pharmaceutically acceptable salts
WO2010072930A1 (en) * 2008-12-24 2010-07-01 Les Laboratoires Servier Novel method for the synthesis of ivabradine
JP2010150259A (en) * 2008-12-24 2010-07-08 Lab Servier New method for synthesizing ivabradine and addition salt thereof with pharmaceutically acceptable acid
KR101064413B1 (en) * 2008-12-24 2011-09-14 르 라보레또레 쎄르비에르 New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
US8097720B2 (en) 2008-12-24 2012-01-17 Les Laboratories Server Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
EP2202225A1 (en) * 2008-12-24 2010-06-30 Les Laboratoires Servier New method for synthesising ivabradine and its added salts with a pharmaceutically acceptable acid.
TWI385153B (en) * 2008-12-24 2013-02-11 Servier Lab New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
FR2940287A1 (en) * 2008-12-24 2010-06-25 Servier Lab NEW PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
JP2012515141A (en) * 2009-01-13 2012-07-05 ジエンス ヘンルイ メデイシンカンパニー リミテッド Ivabradine sulfate and method for producing the same type I crystal
KR101166632B1 (en) 2009-03-31 2012-07-19 르 라보레또레 쎄르비에르 New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
KR101166630B1 (en) 2009-03-31 2012-07-19 르 라보레또레 쎄르비에르 New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
JP2013505225A (en) * 2009-09-18 2013-02-14 レ ラボラトワール セルヴィエ A novel method for the synthesis of ivabradine and its addition salts with pharmaceutically acceptable acids
WO2011098582A2 (en) 2010-02-12 2011-08-18 Krka, D.D., Novo Mesto Novel forms of ivabradine hydrochloride
EP2902384A1 (en) 2010-02-12 2015-08-05 KRKA, D.D., Novo Mesto Forms of ivabradine iydrochloride
WO2011098582A3 (en) * 2010-02-12 2012-03-01 Krka, D.D., Novo Mesto Novel crystalline forms of ivabradine hydrochloride
JP2011168590A (en) * 2010-02-17 2011-09-01 Lab Servier New method for synthesizing ivabradine and addition salt thereof with pharmaceutically acceptable acid
CN103265491A (en) * 2010-02-17 2013-08-28 瑟维尔实验室 New method for synthesising ivabradine and its addition salts
FR2956401A1 (en) * 2010-02-17 2011-08-19 Servier Lab NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID
US8278440B2 (en) 2010-02-17 2012-10-02 Les Laboratoires Servier Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
AU2011200403B2 (en) * 2010-02-17 2015-02-19 Les Laboratoires Servier New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2011101558A1 (en) * 2010-02-17 2011-08-25 Les Laboratoires Servier Novel method for synthesizing ivabradine and the pharmaceutically acceptable acid addition salts thereof
CN103232360B (en) * 2010-02-17 2014-05-21 瑟维尔实验室 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
CN103232360A (en) * 2010-02-17 2013-08-07 瑟维尔实验室 Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
EP2364972A1 (en) * 2010-02-17 2011-09-14 Les Laboratoires Servier New method for synthesising ivabradine and its addition salts
WO2011138625A1 (en) 2010-05-07 2011-11-10 Richter Gedeon Nyrt. Industrial process for the synthesis of ivabradine salts
EA025533B1 (en) * 2010-05-07 2017-01-30 Рихтер Гедеон Нирт. Industrial process for the synthesis of ivabradine salts
WO2011157722A2 (en) 2010-06-14 2011-12-22 Ratiopharm Gmbh Solid ivabradine-containing composition
EP2946772A1 (en) 2010-06-14 2015-11-25 ratiopharm GmbH Solid ivabradine-containing composition
EP2579859A2 (en) 2010-06-14 2013-04-17 Ratiopharm GmbH Solid ivabradine-containing composition
WO2011157721A2 (en) 2010-06-14 2011-12-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition
WO2011157720A2 (en) 2010-06-14 2011-12-22 Ratiopharm Gmbh Ivabradine-containing pharmaceutical composition with modified release
WO2012025940A1 (en) 2010-08-25 2012-03-01 Cadila Healthcare Limited Polymorphic form of ivabradine hydrochloride and process for preparation thereof
EA020735B1 (en) * 2011-02-14 2015-01-30 Ле Лаборатуар Сервье New method for synthesising ivabradine and pharmaceutically acceptable acid addition salts thereof
CN102731400A (en) * 2011-04-11 2012-10-17 山东新时代药业有限公司 Novel ivabradine hydrochloride crystal form and its preparation method and use in preparation of pharmaceutical composition
WO2013017582A1 (en) 2011-08-02 2013-02-07 Sandoz Ag Acetone solvate of ivabradine hydrochloride
US9440924B2 (en) 2011-08-02 2016-09-13 Sandoz Ag Acetone solvate of ivabradine hydrochloride
EP3263556A1 (en) 2011-11-04 2018-01-03 Urquima, S.A. Ivabradine hydrochloride form iv
WO2013064307A1 (en) 2011-11-04 2013-05-10 Urquima, S. A. Ivabradine hydrochloride form iv
US9139531B2 (en) 2011-11-04 2015-09-22 Urquima, S.A. Ivabradine hydrochloride form IV
US9309201B2 (en) 2011-11-04 2016-04-12 Urquima, S.A. Process for preparating ivabradine hydrochloride form IV and methods of treatment of disease using ivabradine hydrochloride form IV
EP2589594A1 (en) 2011-11-04 2013-05-08 Urquima S.A. Ivabradine hydrochloride Form IV
US9382209B2 (en) 2011-11-14 2016-07-05 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
WO2013102919A1 (en) 2011-11-14 2013-07-11 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
EP3156399A1 (en) * 2011-11-14 2017-04-19 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
US9650344B2 (en) 2011-11-14 2017-05-16 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
US9840469B2 (en) 2011-11-14 2017-12-12 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
US9120755B2 (en) 2011-11-14 2015-09-01 Cadila Healthcare Limited Polymorphic forms of ivabradine hydrochloride
EA026510B1 (en) * 2011-12-20 2017-04-28 Ле Лаборатуар Сервье New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2014020534A1 (en) * 2012-07-30 2014-02-06 Biocon Limited Ivabradine hydrochloride and the processes for preparation thereof
WO2014102827A1 (en) * 2012-12-28 2014-07-03 Glenmark Pharmaceuticals Limited; Glenmark Generics Limited Process for preparation of ivabradine
CN103012269A (en) * 2013-01-05 2013-04-03 江苏宇田生物医药科技有限公司 Novel ivabradine hydrochloride crystal form C and preparation method thereof
WO2014114341A1 (en) 2013-01-24 2014-07-31 Synthon Bv Process for making ivabradine
ITMI20130684A1 (en) * 2013-04-24 2014-10-25 Chemo Res S L NEW POLIMORFO OF IVABRADINA CHLORIDRATE AND METHOD FOR ITS PREPARATION
US9809554B2 (en) 2013-05-22 2017-11-07 Olon S.P.A. Process for preparing ivabradine
WO2014188248A1 (en) 2013-05-22 2014-11-27 Laboratorio Chimico Internazionale S.P.A. A process for preparing ivabradine
ITMI20130830A1 (en) * 2013-05-22 2014-11-23 Laboratorio Chimico Int Spa PROCEDURE FOR THE PREPARATION OF IVABRADINA
WO2015022702A3 (en) * 2013-08-10 2015-04-09 Ind-Swift Laboratories Limited Process for preparation of 4,5-dimethoxybenzene derivatives and use in the synthesis of ivabradine and salts thereof
CN104447553A (en) * 2013-09-22 2015-03-25 广东众生药业股份有限公司 Preparation method for ivabradine and intermediate thereof
WO2015048937A1 (en) 2013-10-02 2015-04-09 Zentiva, K.S. A solid form of ivabradine hydrochloride and (s)-mandelic acid and a pharmaceutical composition thereof
CZ305096B6 (en) * 2013-10-02 2015-04-29 Zentiva, K.S. Ivabradine hydrochloride and (S)-mandelic acid solid form and pharmaceutical composition thereof
WO2015001133A1 (en) 2013-12-12 2015-01-08 Synthon B.V. Pharmaceutical composition comprising amorphous ivabradine
WO2015101072A1 (en) * 2014-01-06 2015-07-09 北京莱瑞森医药科技有限公司 S crystal form of ivabradine hydrochloride, and preparation method and pharmaceutical composition thereof
US9676725B2 (en) 2014-01-06 2017-06-13 Beijing Lunarsun Pharmaceutical Co., Ltd. S-crystal form of ivabradine hydrochloride, and preparation method and pharmaceutical composition thereof
WO2016004911A1 (en) 2014-07-10 2016-01-14 Zentiva, K.S. A cocrystal of ivabradine hydrochloride and (r)-mandelic acid and its pharmaceutical composition
CZ305436B6 (en) * 2014-07-10 2015-09-16 Zentiva, K.S. Solid form of ivabradine hydrochloride and (R)-mandelic acid and pharmaceutical composition thereof
CN104230808A (en) * 2014-08-22 2014-12-24 苏州亚宝药物研发有限公司 Amorphous ivabradine hydrochloride, and preparation method and application thereof
WO2016026172A1 (en) * 2014-08-22 2016-02-25 苏州亚宝药物研发有限公司 Amorphous ivabradine hydrochloride, and preparation method therefor and uses thereof
WO2016102423A1 (en) 2014-12-22 2016-06-30 Ratiopharm Gmbh Composition comprising ivabradine in a dissolved form
EP3280399A1 (en) * 2015-04-10 2018-02-14 Alfred E. Tiefenbacher (GmbH & Co. KG) Pharmaceutical composition comprising ivabradine oxalate
EP3366281A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
EP3366282A1 (en) 2017-02-28 2018-08-29 Sanovel Ilac Sanayi ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
WO2018158214A1 (en) 2017-02-28 2018-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
WO2018158304A1 (en) 2017-02-28 2018-09-07 Sanovel Ilac Sanayi Ve Ticaret A.S. Solid oral pharmaceutical compositions of ivabradine
CN107698508A (en) * 2017-10-24 2018-02-16 重庆东得医药科技有限公司 A kind of synthetic method of dehydrogenation Ivabradine
CN107698508B (en) * 2017-10-24 2021-01-05 重庆东得医药科技有限公司 Synthesis method of dehydroivabradine

Also Published As

Publication number Publication date
EP2471780A1 (en) 2012-07-04
KR20100021625A (en) 2010-02-25
EP2162438A4 (en) 2011-07-06
WO2008146308A3 (en) 2010-03-11
ES2528026T3 (en) 2015-02-03
PT2471780E (en) 2015-02-24
RU2473544C2 (en) 2013-01-27
EP2471780B1 (en) 2014-11-26
AR066810A1 (en) 2009-09-16
KR101478855B1 (en) 2015-01-02
RU2009149375A (en) 2011-07-10
US20100179316A1 (en) 2010-07-15
WO2008146308A9 (en) 2009-01-15
JP2010528103A (en) 2010-08-19
EP2162438A2 (en) 2010-03-17
JP5632279B2 (en) 2014-11-26
US8212026B2 (en) 2012-07-03

Similar Documents

Publication Publication Date Title
EP2471780B1 (en) Crystalline Ivabradine Oxalate Salts and Polymorphs Thereof
EP3587400B1 (en) Process for the preparation of a pde4 inhibitor
WO2008035381A2 (en) Process for the preparation of amine derivatives as calcimimetics
EA015777B1 (en) New method for resolution of enantiomers of (3,4-dimethoxy-bicyclo[4.2.0]octa-1,3,5-trien-7-yl)nitrile and their application to the synthesis of ivabradine
CN111630049B (en) Process for preparing 2- (5-methoxyisochroman-1-yl) -4, 5-dihydro-1H-imidazole and bisulphates thereof
EA007743B1 (en) Process for synthesizing derivatives of 1,3,4,6-tetrahydro-2h-3-benzazepin-2-one
KR100464180B1 (en) NEW PROCESS FOR THE PREPARATION OF 11-AMINO-3-CHLORO-6,11-DIHYDRO-5,5-DIOXO-6-METHYL-DIBENZO[c,f][1,2]THIAZEPINE AND APPLICATION TO THE SYNTHESIS OF TIANEPTINE
WO2011104723A2 (en) Acid addition salts of ivabradine and preparation thereof
KR20180129854A (en) Improved Preparation of Butorphanol Tartrate
WO2013132514A2 (en) A novel process for the preparation of (r)-5-[2-[(5, 6-diethyl-2, 3-dihydro-1h-inden-2-yl) amino]-1-hydroxyethyl]-8-hydroxy quinolin-2(1h)-one
WO2011033194A1 (en) Novel method for synthesizing ivabradine and the addition salts thereof with a pharmaceutically acceptable acid
JP5021004B2 (en) A novel method for synthesis of agomelatine
KR20160093698A (en) Novel method for the synthesis of agomelatine
EP2327684B1 (en) A process for the preparation of cinacalcet and intermediates thereof
CN107935866B (en) Preparation method of dapoxetine hydrochloride impurity
WO2012127483A1 (en) Processes for the preparation of intermediates of n-[2-(7-methoxy-1-naphthyl) ethyl] acetamide
EA027080B1 (en) Process for the synthesis of (2e)-3-(3,4- dimethoxyphenyl)prop-2-enenitrile, application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
KR101575736B1 (en) New process for the synthesis of 3-(2-bromo-4,5-dimethoxyphenyl)propanenitrile, and application in the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2016046833A2 (en) Improved processes for the preparation of agomelatine using novel intermediates
WO2009139001A2 (en) An improved process for the preparation of oxcarbazepine
KR101479986B1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
WO2019202611A1 (en) An improved process for the synthesis of ivabradine and its pharmaceutically acceptable salts
WO2013054273A9 (en) Process for the preparation of agomelatine
EP2785681A1 (en) Process for the preparation of agomelatine
WO2017138017A1 (en) Process for the preparation of benzazepine-2-one derivative

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08763748

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2010509952

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 12602348

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008763748

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 20097026828

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2009149375

Country of ref document: RU